{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000197","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.488525+00:00","generated_at":"2026-06-07T00:23:23.025539+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Capricor receives $10M milestone from Nippon Shinyaku; HOPE-3 trial continues","bullets":["Milestone payment of $10.0 million received from Nippon Shinyaku under 2022 commercialization agreement.","Payment triggered by favorable interim futility analysis from Data Safety Monitoring Board for HOPE-3 trial.","DSMB recommended continuation of HOPE-3 trial as planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000197","json":"https://secwatch.observer/filing/0001558370-24-000197.json","markdown":"https://secwatch.observer/filing/0001558370-24-000197.md","text":"https://secwatch.observer/filing/0001558370-24-000197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024000197/0001558370-24-000197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024000197/capr-20240111x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:23:23.025539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}